CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 172 enrolled
Drug / intervention
Pemetrexed +2 moredrug
Likely dose
Pemetrexed 500 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00892710
NCT00892710Phase 2Completed
CompareCT.gov

Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2

SCRI Development Innovations, LLC·interventional·Posted May 4, 2009·Updated May 15, 2015

In Brief

A Phase 2 clinical trial evaluating Pemetrexed, Bevacizumab, and 1 other intervention for Non Small Cell Lung Cancer. Completed, enrolled 172 participants across 27 sites.

Detailed Summary

The purpose of this trial is to evaluate three treatment regimens in patients with stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) with a performance status of 2 and who were not previously treated.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 4, 2009
Enrollment StartJun 1, 2009
Primary CompletionJul 1, 2014
Study CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 17.2 years ago

Interventions

Pemetrexeddrug

500 mg/m2 IV given over 10 minutes every 21 days

Bevacizumabdrug

15 mg/kg IV every 21 days

Carboplatindrug

AUC=5 IV every 21 days